News


Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis

  • Oral presentation to outline the development and preclinical evaluation of KY1049, the first fully human Factor VIII-mimetic bispecific antibody
  • First development candidate generated using the IntelliSelect® Bispecific platform expected to enter clinical studies in 2021/22

 

Cambridge, UK; October 3, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced that an abstract describing KY1049, the Company’s fully human Factor VIII (FVIII)-mimetic bispecific antibody, will be presented at the European Congress on Thrombosis and Haemostasis (ECTH) in Glasgow, UK October 3, 2019.